Anti-central fatigue effects of myelophil in 5-HTergic hyperactivity mice model.
Kang, Ji-Yun, Baek, Dong-Cheol, Lee, Jin-Seok et al. · BMC complementary medicine and therapies · 2025 · DOI
Quick Summary
This study tested a herbal supplement called Myelophil (made from two traditional Korean medicinal plants) in mice that had high serotonin levels—a condition researchers believe may contribute to ME/CFS fatigue. Mice given Myelophil showed improvements in fatigue-related behaviors and pain sensitivity compared to untreated mice. The results suggest this supplement may help by adjusting how the brain handles serotonin.
Why It Matters
This study provides preliminary mechanistic evidence that serotonergic dysregulation may contribute to ME/CFS-type fatigue and identifies a potential therapeutic target. If validated in humans, Myelophil could represent a novel treatment avenue for patients with ME/CFS, particularly those with evidence of serotonergic involvement. Understanding these mechanisms helps clarify biological underpinnings of central fatigue.
Observed Findings
Fluoxetine treatment increased serotonin activity in raphe nuclei and induced fatigue-like behaviors across five behavioral tests
Myelophil (100 mg/kg) significantly improved fatigue-related behaviors and reduced pain sensitivity in fluoxetine-treated mice
Myelophil normalized serotonin transporter (5-HTT) and VMAT2 protein expression in raphe nuclei
Myelophil restored c-Fos and BDNF levels in raphe nuclei to near-normal ranges
Ascorbic acid control showed no significant protective effects against fluoxetine-induced fatigue
Inferred Conclusions
Serotonergic hyperactivity in raphe nuclei may contribute to central fatigue phenotypes similar to ME/CFS
Myelophil exerts anti-fatigue effects through modulation of serotonin transporter function and neurotrophic signaling
The herbal extract may represent a therapeutic strategy for fatigue associated with dysregulated serotonergic activity
Remaining Questions
Will Myelophil demonstrate similar efficacy in human ME/CFS patients with documented serotonergic abnormalities?
Which specific phytochemical constituents of Myelophil are responsible for the observed serotonin-modulating effects?
What This Study Does Not Prove
This animal model study does not prove that elevated serotonin causes ME/CFS in humans or that Myelophil will be effective in ME/CFS patients. The fluoxetine-induced mouse model mimics only one aspect of potential pathophysiology and may not capture the full complexity of the human disease. Rodent findings frequently do not translate to human clinical benefit.
Tags
Symptom:PainFatigue
Biomarker:Gene ExpressionBlood Biomarker
Method Flag:PEM Not DefinedNo ControlsExploratory Only